Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, characterized by clonal expansion of mature-appearing CD5+ B lymphocytes in blood, bone marrow, and lymphoid tissues. The clinical course is highly variable, ranging from indolent disease requiring no treatment to aggressive forms. Prognosis is stratified by IGHV mutation status, cytogenetics (del(17p), del(11q), del(13q)), and TP53 mutations. Treatment has been revolutionized by BTK inhibitors (ibrutinib, acalabrutinib) and BCL2 inhibitors (venetoclax), enabling chemotherapy-free regimens with deep remissions.
Ask a research question about Chronic Lymphocytic Leukemia. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Chronic Lymphocytic Leukemia
creation_date: '2026-01-26T02:55:13Z'
updated_date: '2026-05-08T20:47:43Z'
description: >-
Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries,
characterized by clonal expansion of mature-appearing CD5+ B lymphocytes in blood,
bone marrow, and lymphoid tissues. The clinical course is highly variable, ranging
from indolent disease requiring no treatment to aggressive forms. Prognosis is
stratified by IGHV mutation status, cytogenetics (del(17p), del(11q), del(13q)),
and TP53 mutations. Treatment has been revolutionized by BTK inhibitors (ibrutinib,
acalabrutinib) and BCL2 inhibitors (venetoclax), enabling chemotherapy-free regimens
with deep remissions.
categories:
- Hematologic Malignancy
- B-cell Neoplasm
- Chronic Leukemia
- Lymphoproliferative Disorder
parents:
- B-cell neoplasm
epidemiology:
- name: Most common adult leukemia
description: Chronic lymphocytic leukemia is the most common type of leukemia in adults.
evidence:
- reference: PMID:41572562
reference_title: "\"Leukemic pernio\": perniosis-like presentations of chronic lymphocytic leukemia."
supports: SUPPORT
snippet: "Chronic lymphocytic leukemia (CLL) is the most common type of leukemia in adults."
explanation: This abstract explicitly states that CLL is the most common adult leukemia.
has_subtypes:
- name: IGHV Mutated CLL
description: >-
CLL with somatic hypermutation of immunoglobulin heavy chain variable region
genes (at least 2% deviation from germline). Associated with favorable prognosis,
lower risk of progression, and better responses to chemoimmunotherapy. Represents
post-germinal center B-cell origin.
- name: IGHV Unmutated CLL
description: >-
CLL without significant IGHV somatic hypermutation (less than 2% deviation from
germline). Associated with more aggressive course, higher risk of progression,
and inferior outcomes with chemoimmunotherapy. May benefit particularly from
novel targeted agents.
pathophysiology:
- name: B-cell Receptor Signaling Dysregulation
description: >-
CLL cells exhibit constitutive B-cell receptor (BCR) signaling, either through
autonomous signaling or antigen-driven activation. This chronic BCR stimulation
activates downstream kinases including BTK, PI3K, and SYK, driving proliferation
and survival. BCR signaling intensity correlates with clinical aggressiveness.
cell_types:
- preferred_term: mature B cell
term:
id: CL:0000785
label: mature B cell
biological_processes:
- preferred_term: B cell activation
modifier: INCREASED
term:
id: GO:0042113
label: B cell activation
downstream:
- target: BTK Pathway Activation
description: BCR engagement activates BTK-mediated survival signaling
- target: Microenvironmental Survival Signals
description: BCR signaling facilitates interaction with supportive niches
- name: BTK Pathway Activation
description: >-
Bruton tyrosine kinase (BTK) is essential for BCR signaling and CLL cell survival.
BTK activation promotes NF-kB signaling, cell adhesion, and tissue homing.
BTK inhibitors disrupt these signals, mobilizing CLL cells from protective
tissue microenvironments and inducing apoptosis.
biological_processes:
- preferred_term: signal transduction
modifier: INCREASED
term:
id: GO:0007165
label: signal transduction
downstream:
- target: NF-kB Activation and Survival
description: BTK activates NF-kB-mediated anti-apoptotic gene expression
- name: Microenvironmental Survival Signals
description: >-
CLL cells depend on interactions with the tissue microenvironment including
nurse-like cells, T cells, and stromal cells in lymph nodes and bone marrow.
These interactions provide survival signals through chemokines, cytokines,
and direct cell contact. Disrupting these interactions is therapeutically
important.
locations:
- preferred_term: lymph node
term:
id: UBERON:0000029
label: lymph node
- preferred_term: bone marrow
term:
id: UBERON:0002371
label: bone marrow
cell_types:
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
downstream:
- target: CLL Cell Accumulation
description: Microenvironmental support enables CLL expansion
- name: NF-kB Activation and Survival
description: >-
NF-kB transcription factors are constitutively activated in CLL and promote
expression of anti-apoptotic genes including BCL2, MCL1, and XIAP. This
contributes to the apoptosis resistance characteristic of CLL cells.
biological_processes:
- preferred_term: apoptotic process
modifier: DECREASED
term:
id: GO:0006915
label: apoptotic process
downstream:
- target: CLL Cell Accumulation
description: Anti-apoptotic signaling enables CLL cell accumulation
- name: CLL Cell Accumulation
description: >-
The combination of defective apoptosis, microenvironmental support, and
low-level proliferation leads to progressive accumulation of clonal B cells.
CLL is primarily a disease of accumulation rather than rapid proliferation.
cell_types:
- preferred_term: B cell
term:
id: CL:0000236
label: B cell
histopathology:
- name: Small B-Cell Clonal Expansion
finding_term:
preferred_term: Small Lymphocytic Lymphoma
term:
id: NCIT:C7540
label: Small Lymphocytic Lymphoma
frequency: VERY_FREQUENT
description: Chronic lymphocytic leukemia is characterized by clonal expansion of CLL B cells.
evidence:
- reference: PMID:29670635
reference_title: "Chronic Lymphocytic Leukemia B-Cell Normal Cellular Counterpart: Clues From a Functional Perspective."
supports: SUPPORT
snippet: "Chronic lymphocytic leukemia (CLL) is characterized by the clonal expansion of"
explanation: Abstract describes CLL as characterized by clonal expansion of CLL B cells.
phenotypes:
- category: Hematologic
name: Lymphoproliferative Disorder
frequency: VERY_FREQUENT
diagnostic: true
description: >-
Persistent elevation of blood lymphocyte count (at least 5000/uL clonal
B lymphocytes) is required for CLL diagnosis. Many patients are diagnosed
incidentally from routine blood tests.
phenotype_term:
preferred_term: Lymphoproliferative disorder
term:
id: HP:0005523
label: Lymphoproliferative disorder
- category: Lymphatic
name: Lymphadenopathy
frequency: VERY_FREQUENT
description: >-
Enlarged lymph nodes are common, may be generalized, and can become
massive. Lymph node involvement is incorporated in staging systems.
phenotype_term:
preferred_term: Lymphadenopathy
term:
id: HP:0002716
label: Lymphadenopathy
evidence:
- reference: PMID:1139039
reference_title: Clinical staging of chronic lymphocytic leukemia.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "stage 1, lymphocytosis with enlarged nodes"
explanation: The Rai staging system defines Stage I CLL by the presence of lymphadenopathy (enlarged nodes), confirming its clinical significance.
- category: Abdominal
name: Splenomegaly
frequency: FREQUENT
description: >-
Spleen enlargement from CLL infiltration. Massive splenomegaly may
cause cytopenias from sequestration.
phenotype_term:
preferred_term: Splenomegaly
term:
id: HP:0001744
label: Splenomegaly
evidence:
- reference: PMID:1139039
reference_title: Clinical staging of chronic lymphocytic leukemia.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "stage II, lymphocytosis with enlarged spleen or liver or both"
explanation: The Rai staging system defines Stage II CLL by the presence of splenomegaly or hepatomegaly, confirming splenomegaly as a key clinical feature.
- category: Hematologic
name: Anemia
frequency: FREQUENT
description: >-
Anemia may result from bone marrow infiltration, autoimmune hemolytic
anemia (AIHA), or hypersplenism.
phenotype_term:
preferred_term: Anemia
term:
id: HP:0001903
label: Anemia
- category: Hematologic
name: Thrombocytopenia
frequency: FREQUENT
description: >-
Low platelet count from marrow infiltration, immune thrombocytopenia
(ITP), or hypersplenism.
phenotype_term:
preferred_term: Thrombocytopenia
term:
id: HP:0001873
label: Thrombocytopenia
- category: Infectious
name: Recurrent Infections
frequency: FREQUENT
description: >-
Increased susceptibility to bacterial and viral infections due to
hypogammaglobulinemia and immune dysfunction. Herpes zoster and
respiratory infections are common.
phenotype_term:
preferred_term: Recurrent infections
term:
id: HP:0002719
label: Recurrent infections
evidence:
- reference: PMID:18755702
reference_title: The immunodeficiency of chronic lymphocytic leukaemia.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Patients with chronic lymphocytic leukaemia (CLL) have progressive immunodeficiency and infection is the commonest cause of death."
explanation: This authoritative review establishes that infection due to immunodeficiency is the leading cause of death in CLL patients.
- category: Constitutional
name: Night Sweats
frequency: OCCASIONAL
description: >-
B symptoms including night sweats indicate more active disease and
may warrant treatment initiation.
phenotype_term:
preferred_term: Night sweats
term:
id: HP:0030166
label: Night sweats
- category: Constitutional
name: Weight Loss
frequency: OCCASIONAL
description: >-
Unintentional weight loss is a B symptom indicating active disease.
phenotype_term:
preferred_term: Weight loss
term:
id: HP:0001824
label: Weight loss
biochemical:
- name: Flow Cytometry Immunophenotyping
notes: >-
CLL cells are CD5+, CD19+, CD23+, CD20 dim, surface Ig dim. The
characteristic immunophenotype distinguishes CLL from other B-cell
lymphomas and mantle cell lymphoma (CD5+ but CD23-).
- name: IGHV Mutation Analysis
notes: >-
Sequencing of immunoglobulin heavy chain variable region determines
mutational status. Mutated IGHV (at least 2% difference from germline)
indicates favorable prognosis.
genetic:
- name: TP53 Mutation/del(17p)
association: High-Risk Prognostic Marker
notes: >-
TP53 alterations (mutation or del(17p)) occur in 5-10% at diagnosis,
higher in relapsed disease. Confer resistance to chemoimmunotherapy
and poor prognosis. BTK and BCL2 inhibitors remain effective.
- name: del(11q)/ATM
association: Intermediate-Risk Marker
notes: >-
Deletion of 11q23 affects the ATM gene, impairing DNA damage responses.
Associated with bulky lymphadenopathy and intermediate prognosis.
May benefit from targeted therapies.
- name: del(13q)
association: Favorable Prognostic Marker
notes: >-
Isolated del(13q14) is the most common cytogenetic abnormality in CLL
and is associated with favorable prognosis when present alone. This
region contains microRNA genes miR-15a and miR-16-1.
- name: IGHV
association: Prognostic Marker
notes: >-
IGHV mutation status is one of the strongest prognostic markers in CLL.
Mutated IGHV indicates post-germinal center origin with better prognosis.
Unmutated IGHV indicates more aggressive disease course.
treatments:
- name: Ibrutinib
description: >-
First-in-class irreversible BTK inhibitor that disrupts BCR signaling,
mobilizes CLL cells from tissue niches, and induces apoptosis.
Effective in all risk groups including TP53-mutated CLL. Continuous
therapy until progression.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
therapeutic_agent:
- preferred_term: ibrutinib
term:
id: CHEBI:76612
label: ibrutinib
evidence:
- reference: PMID:26639149
reference_title: Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "ibrutinib resulted in significantly longer progression-free survival than did chlorambucil (median, not reached vs. 18.9 months), with a risk of progression or death that was 84% lower with ibrutinib than that with chlorambucil"
explanation: The landmark RESONATE-2 trial demonstrated ibrutinib's superiority in treatment-naive elderly CLL patients with 84% reduction in risk of progression or death.
- name: Acalabrutinib
description: >-
Second-generation selective BTK inhibitor with improved kinase selectivity
and potentially fewer off-target effects than ibrutinib. Effective as
monotherapy or combined with obinutuzumab.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
therapeutic_agent:
- preferred_term: acalabrutinib
term:
id: CHEBI:167707
label: acalabrutinib
- name: Venetoclax plus Obinutuzumab
description: >-
BCL2 inhibitor venetoclax combined with anti-CD20 antibody obinutuzumab
achieves high rates of undetectable MRD and enables time-limited
therapy (12 months). Particularly effective in treatment-naive CLL.
treatment_term:
preferred_term: targeted therapy
term:
id: NCIT:C93352
label: Targeted Therapy
therapeutic_agent:
- preferred_term: venetoclax
term:
id: CHEBI:133021
label: venetoclax
evidence:
- reference: PMID:30523712
reference_title: 'Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study.'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The MURANO study demonstrated significant progression-free survival (PFS) benefit for fixed-duration venetoclax-rituximab compared with bendamustine-rituximab in relapsed/refractory chronic lymphocytic leukemia."
explanation: The MURANO Phase III study demonstrated venetoclax-rituximab's superiority in relapsed/refractory CLL with significantly improved progression-free survival.
- name: Chemoimmunotherapy (FCR)
description: >-
Fludarabine, cyclophosphamide, and rituximab combination was standard
for fit patients with mutated IGHV without del(17p)/TP53 mutation.
Can achieve long remissions in this favorable subgroup but largely
replaced by targeted agents.
treatment_term:
preferred_term: chemotherapy
term:
id: MAXO:0000647
label: chemotherapy
therapeutic_agent:
- preferred_term: cyclophosphamide
term:
id: CHEBI:4027
label: cyclophosphamide
- name: Watch and Wait
description: >-
Asymptomatic early-stage CLL does not require immediate treatment.
Active surveillance with monitoring for disease progression or
treatment indications (cytopenias, symptomatic disease, rapid
progression) is appropriate for many patients.
treatment_term:
preferred_term: surveillance for malignancies
term:
id: MAXO:0001492
label: surveillance for malignancies
disease_term:
preferred_term: chronic lymphocytic leukemia
term:
id: MONDO:0004948
label: B-cell chronic lymphocytic leukemia
classifications:
icdo_morphology:
classification_value: Leukemia
harrisons_chapter:
- classification_value: ONCOLOGY_HEMATOLOGY
references:
- reference: DOI:10.1002/ajh.25595
title: 'Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment'
found_in:
- Chronic_Lymphocytic_Leukemia-deep-research-falcon.md
findings:
- statement: Disease overviewChronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries.
supporting_text: Disease overviewChronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries.
evidence:
- reference: DOI:10.1002/ajh.25595
reference_title: 'Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment'
supports: SUPPORT
evidence_source: OTHER
snippet: Disease overviewChronic lymphocytic leukemia (CLL) is the commonest leukemia in western countries.
explanation: Deep research cited this publication as relevant literature for Chronic Lymphocytic Leukemia.
- reference: DOI:10.1007/s00277-024-05823-8
title: 'Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE'
found_in:
- Chronic_Lymphocytic_Leukemia-deep-research-falcon.md
findings:
- statement: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has different epidemiology in Chinese vs.
supporting_text: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has different epidemiology in Chinese vs.
evidence:
- reference: DOI:10.1007/s00277-024-05823-8
reference_title: 'Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) in China: a subgroup of ALPINE'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has different epidemiology in Chinese vs.
explanation: Deep research cited this publication as relevant literature for Chronic Lymphocytic Leukemia.
- reference: DOI:10.1038/s41375-022-01802-y
title: 'Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY'
found_in:
- Chronic_Lymphocytic_Leukemia-deep-research-falcon.md
findings:
- statement: Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status.
supporting_text: Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status.
evidence:
- reference: DOI:10.1038/s41375-022-01802-y
reference_title: 'Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Recent evidence suggests that the prognostic impact of gene mutations in patients with chronic lymphocytic leukemia (CLL) may differ depending on the immunoglobulin heavy variable (IGHV) gene somatic hypermutation (SHM) status.
explanation: Deep research cited this publication as relevant literature for Chronic Lymphocytic Leukemia.
- reference: DOI:10.1038/s41375-024-02224-8
title: NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia
found_in:
- Chronic_Lymphocytic_Leukemia-deep-research-falcon.md
findings:
- statement: NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia
supporting_text: Loss-of-function mutations in NFKBIE, which encodes for the NF-κB inhibitor IκBε, are frequent in chronic lymphocytic leukemia (CLL) and certain other B-cell malignancies and have been associated with accelerated disease progression and inferior responses to chemotherapy.
evidence:
- reference: DOI:10.1038/s41375-024-02224-8
reference_title: NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Loss-of-function mutations in NFKBIE, which encodes for the NF-κB inhibitor IκBε, are frequent in chronic lymphocytic leukemia (CLL) and certain other B-cell malignancies and have been associated with accelerated disease progression and inferior responses to chemotherapy.
explanation: Deep research cited this publication as relevant literature for Chronic Lymphocytic Leukemia.
- reference: DOI:10.1038/s41419-024-06528-6
title: Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia
found_in:
- Chronic_Lymphocytic_Leukemia-deep-research-falcon.md
findings:
- statement: The tumor microenvironment (TME) plays a central role in the pathogenesis of chronic lymphocytic leukemia (CLL), contributing to disease progression and chemoresistance.
supporting_text: The tumor microenvironment (TME) plays a central role in the pathogenesis of chronic lymphocytic leukemia (CLL), contributing to disease progression and chemoresistance.
evidence:
- reference: DOI:10.1038/s41419-024-06528-6
reference_title: Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: The tumor microenvironment (TME) plays a central role in the pathogenesis of chronic lymphocytic leukemia (CLL), contributing to disease progression and chemoresistance.
explanation: Deep research cited this publication as relevant literature for Chronic Lymphocytic Leukemia.
- reference: DOI:10.1038/s41467-023-37648-w
title: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
found_in:
- Chronic_Lymphocytic_Leukemia-deep-research-falcon.md
findings:
- statement: Data on long-term outcomes and biological drivers associated with depth of remission after BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are limited.
supporting_text: Data on long-term outcomes and biological drivers associated with depth of remission after BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are limited.
evidence:
- reference: DOI:10.1038/s41467-023-37648-w
reference_title: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Data on long-term outcomes and biological drivers associated with depth of remission after BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are limited.
explanation: Deep research cited this publication as relevant literature for Chronic Lymphocytic Leukemia.
- reference: DOI:10.1182/blood-2017-09-806398
title: iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
found_in:
- Chronic_Lymphocytic_Leukemia-deep-research-falcon.md
findings:
- statement: The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL.
supporting_text: The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL.
evidence:
- reference: DOI:10.1182/blood-2017-09-806398
reference_title: iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
supports: SUPPORT
evidence_source: OTHER
snippet: The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL.
explanation: Deep research cited this publication as relevant literature for Chronic Lymphocytic Leukemia.
- reference: DOI:10.3324/haematol.2023.284693
title: The diversity of the microbiome impacts chronic lymphocytic leukemia development in mice and humans
found_in:
- Chronic_Lymphocytic_Leukemia-deep-research-falcon.md
findings:
- statement: The gut microbiota plays a critical role in maintaining a healthy human body and its dysregulation is associated with various diseases.
supporting_text: The gut microbiota plays a critical role in maintaining a healthy human body and its dysregulation is associated with various diseases.
evidence:
- reference: DOI:10.3324/haematol.2023.284693
reference_title: The diversity of the microbiome impacts chronic lymphocytic leukemia development in mice and humans
supports: SUPPORT
evidence_source: MODEL_ORGANISM
snippet: The gut microbiota plays a critical role in maintaining a healthy human body and its dysregulation is associated with various diseases.
explanation: Deep research cited this publication as relevant literature for Chronic Lymphocytic Leukemia.
- reference: DOI:10.3324/haematol.2024.285754
title: 'Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial'
found_in:
- Chronic_Lymphocytic_Leukemia-deep-research-falcon.md
findings:
- statement: Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation.
supporting_text: Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation.
evidence:
- reference: DOI:10.3324/haematol.2024.285754
reference_title: 'Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial'
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation.
explanation: Deep research cited this publication as relevant literature for Chronic Lymphocytic Leukemia.
- reference: DOI:10.6004/jnccn.2024.7020
title: Clinical Risks for Chronic Lymphocytic Leukemia
found_in:
- Chronic_Lymphocytic_Leukemia-deep-research-falcon.md
findings:
- statement: Our understanding of risk factors for the development of chronic lymphocytic leukemia (CLL) is still incomplete and includes genetic and environmental factors.
supporting_text: Our understanding of risk factors for the development of chronic lymphocytic leukemia (CLL) is still incomplete and includes genetic and environmental factors.
evidence:
- reference: DOI:10.6004/jnccn.2024.7020
reference_title: Clinical Risks for Chronic Lymphocytic Leukemia
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: Our understanding of risk factors for the development of chronic lymphocytic leukemia (CLL) is still incomplete and includes genetic and environmental factors.
explanation: Deep research cited this publication as relevant literature for Chronic Lymphocytic Leukemia.
Question: You are an expert researcher providing comprehensive, well-cited information.
Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies
Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.
Please provide a comprehensive research report on Chronic Lymphocytic Leukemia covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.
For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.
Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed
Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
Search first: CTD, PubMed, PheGenI, GxE databases
Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC
For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype
Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser
Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
Search first: CDC databases, WHO, PubMed, NHANES
Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON
Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc
Search first: Gene Ontology (GO), Reactome, KEGG, PubMed
Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
Search first: ImmPort, Immunome Database, IEDB, Gene Ontology
Search first: PubMed, Gene Ontology, Reactome
Search first: BRENDA, UniProt, KEGG, OMIM, PubMed
Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types
Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
Search first: OMIM, Orphanet, HPO, PubMed
Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen
For each treatment, suggest MAXO (Medical Action Ontology) terms where applicable.
Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database
Search first: CDC, WHO, behavioral intervention databases, Cochrane Library
Search first: NSGC resources, ACMG guidelines, GeneReviews
Search first: Clinical guidelines, FDA approvals, PubMed
Search first: NCBI Taxonomy
Search first: VBO (Vertebrate Breed Ontology)
Search first: NCBI Gene
Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, MAXO, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease
This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (MAXO terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details
Chronic lymphocytic leukemia (CLL) is a clonal, typically CD5-positive mature B-cell neoplasm with accumulation of malignant B cells in blood, bone marrow, lymph nodes, and spleen. (hallek2019chroniclymphocyticleukemia pages 1-2)
A widely used operational definition is based on peripheral blood involvement: the iwCLL (International Workshop on CLL) 2018 guidelines state that the diagnosis of CLL requires ≥5 × 10^9/L clonal B lymphocytes in peripheral blood, sustained for at least 3 months, with clonality confirmed by light-chain restriction on flow cytometry. (hallek2018iwcllguidelinesfor pages 1-2)
Direct abstract quote (iwCLL 2018): “The diagnosis of CLL requires the presence of ≥5 × 10^9/L B lymphocytes in the peripheral blood, sustained for at least 3 months. The clonality of these B lymphocytes needs to be confirmed … using flow cytometry.” (hallek2018iwcllguidelinesfor pages 1-2)
Direct abstract quote (JAMA 2023): “Chronic lymphocytic leukemia (CLL), defined by a minimum of 5 × 10^9/L monoclonal B cells in the blood …” (shadman2023diagnosisandtreatment pages 1-2)
From the iwCLL guideline text, the World Health Organization (WHO) classification is referenced conceptually: CLL is described as a “leukemic … lymphoma,” distinguishable from small lymphocytic lymphoma (SLL) largely by leukemic (blood) manifestation. (hallek2018iwcllguidelinesfor pages 1-2)
Most content here derives from aggregated, disease-level resources (international consensus guidelines and peer-reviewed reviews) rather than individual EHR-derived patient records. (hallek2018iwcllguidelinesfor pages 1-2, shadman2023diagnosisandtreatment pages 1-2)
CLL etiology is multifactorial, involving inherited susceptibility plus acquired somatic lesions and microenvironmental signals.
Familial/genetic susceptibility: A 2024 expert review on CLL risk factors (JNCCN) concludes that “CLL is one of the most familial of all cancers” and that “Genome-wide association studies have identified many common variants with low relative risks, whereas exome-wide rare variant analysis has implicated ATM in CLL causation.” (brown2024clinicalrisksfor pages 1-2)
Direct abstract quote (Brown 2024, JNCCN): “CLL is one of the most familial of all cancers, yet common high-penetrance risk alleles have not been identified. Genome-wide association studies have identified many common variants with low relative risks, whereas exome-wide rare variant analysis has implicated ATM in CLL causation.” (brown2024clinicalrisksfor pages 1-2)
Environmental factors: The same 2024 expert review highlights limitations of exposure ascertainment but notes: “Agent Orange and glyphosate herbicides have perhaps the most data to support their role.” (brown2024clinicalrisksfor pages 1-2)
Precursor condition: The review emphasizes that CLL is preceded by monoclonal B-cell lymphocytosis (MBL): “CLL is preceded by a precursor condition called monoclonal B-cell lymphocytosis (MBL) … Although virtually all people with CLL have a preceding MBL phase, most people with MBL will not develop CLL.” (brown2024clinicalrisksfor pages 1-2)
No protective genetic or environmental factors were directly extractable from the available evidence.
Not directly extractable from the available evidence.
From a 2023 JAMA clinical review: - Asymptomatic at diagnosis: ~70–80% (shadman2023diagnosisandtreatment pages 1-2) - Incidental lymphocytosis: ~70% (shadman2023diagnosisandtreatment pages 1-2) - Symptomatic at presentation: ~30% (shadman2023diagnosisandtreatment pages 1-2) - Enlarged lymph nodes: ~50% (shadman2023diagnosisandtreatment pages 1-2) - Hepatosplenomegaly-related symptoms: ~20–50% (shadman2023diagnosisandtreatment pages 1-2) - B symptoms (fever, drenching night sweats, weight loss ≥10%/6 months): ~5–10% (shadman2023diagnosisandtreatment pages 1-2) - Autoimmune cytopenias: hemolytic anemia up to 10%, immune thrombocytopenia up to 2% (shadman2023diagnosisandtreatment pages 1-2) - Hypogammaglobulinemia with frequent infections: up to 10% (shadman2023diagnosisandtreatment pages 1-2)
(These are ontology suggestions and require mapping/validation against HPO.) - Lymphocytosis (HP:0001974) - Lymphadenopathy (HP:0002716) - Splenomegaly (HP:0001744) - Hepatomegaly (HP:0002240) - Fever (HP:0001945) - Night sweats (HP:0030166) - Weight loss (HP:0001824) - Anemia (HP:0001903) - Thrombocytopenia (HP:0001873) - Hypogammaglobulinemia (HP:0004313) - Recurrent infections (HP:0002719)
A widely used risk stratification approach in CLL includes interphase FISH and key recurrent lesions. A 2019 American Journal of Hematology update summarizes approximate frequencies: - del(13q14): ~55% (hallek2019chroniclymphocyticleukemia pages 1-2) - Trisomy 12: ~10–20% (hallek2019chroniclymphocyticleukemia pages 1-2) - del(17p) in chemo-naïve patients: ~5–8% (often implicating TP53) (hallek2019chroniclymphocyticleukemia pages 1-2)
Additionally, a large multicenter cohort (ERIC/HARMONY; 4580 patients) reported baseline cytogenetics frequencies: del(13q) 42%, trisomy 12 13%, del(11q) 11%, del(17p) 5%. (mansouri2023differentprognosticimpact pages 1-2)
A large 2023 Leukemia study (ERIC in HARMONY) assessed nine recurrent genes (BIRC3, EGR2, MYD88, NFKBIE, NOTCH1, POT1, SF3B1, TP53, XPO1) in 4580 pre-treatment samples: - Mutations detected in 34.7% of patients; frequencies across genes ranged 2.3–9.8%; NOTCH1 was most frequent. (mansouri2023differentprognosticimpact pages 1-2) - Mutations in all genes except MYD88 were associated with significantly shorter time-to-first-treatment (TTFT) in multivariable analysis. (mansouri2023differentprognosticimpact pages 1-2) - Prognostic impact differed by IGHV SHM status: SF3B1 and XPO1 were adverse in both IGHV-mutated and unmutated CLL; TP53/BIRC3/EGR2 adverse in unmutated CLL only; NOTCH1/NFKBIE adverse in IGHV-mutated CLL only. (mansouri2023differentprognosticimpact pages 1-2)
Direct abstract quote (Mansouri 2023): “Mutations were detected in 1588 (34.7%) patients … In both univariate and multivariate analyses, mutations in all genes except MYD88 were associated with a significantly shorter TTFT.” (mansouri2023differentprognosticimpact pages 1-2)
A 2024 Leukemia mechanistic study reports that loss-of-function NFKBIE mutations are selected by microenvironmental NF-κB-activating signals and promote immune escape (exhausted CD8+ T cells; increased PD-L1 on malignant B cells) and are associated with inferior outcomes to ibrutinib in NFKBIE-mutated patients. (bonato2024nfkbiemutationsare pages 1-2)
Direct abstract quote (Bonato 2024): “NFKBIE-mutated CLL cells are selected by microenvironmental signals that activate the NF-κB pathway … allowing for immune escape, including expansion of CD8+ T-cells with an exhausted phenotype and increased PD-L1 expression on the malignant B-cells.” (bonato2024nfkbiemutationsare pages 1-2)
Evidence summary from an authoritative 2024 risk-factor review indicates environmental risks are difficult to quantify retrospectively, but Agent Orange and glyphosate herbicides have the strongest current supporting data among exposures discussed. (brown2024clinicalrisksfor pages 1-2)
No infectious causation was supported by the retrieved evidence.
Soluble factor–mediated T-cell suppression (IL-9): A 2024 Cell Death & Disease paper provides direct evidence that soluble factors secreted by CLL cells can drive PD-1 upregulation and functional impairment of cytotoxic T lymphocytes (CTLs), including in the Eμ-TCL1 model.
Direct abstract quote (Boncompagni 2024): “healthy CTLs cultured in media conditioned by leukemic cells from CLL patients or Eμ-TCL1 mice upregulate the exhaustion marker PD-1 and become unable to form functional [immune synapses] and kill target cells.” (boncompagni2024leukemiccellsecretedinterleukin9 pages 1-3)
It further identifies IL-9 as a key mediator: “IL-9, but not IL-10, mediates both the enhancement in PD-1 expression and the suppression of effector functions … highlighting a new suppressive mechanism and a novel potential therapeutical target in CLL.” (boncompagni2024leukemiccellsecretedinterleukin9 pages 1-3)
Microbiome diversity and CLL aggressiveness: A 2024 Haematologica study links gut microbiome diversity with clinical course in humans and disease kinetics in Eμ-TCL1 mice.
Direct abstract quote (Faitová 2024): “CLL patients with lower microbiome diversity … suffered from a more advanced or aggressive form of CLL. In the Eµ-TCL1 mouse model … we observed a faster course of disease when mice were housed in high hygiene conditions … associated with a lower microbiome diversity …” (faitova2024thediversityof pages 1-2)
CLL involves: - Peripheral blood (leukemic manifestation used in diagnostic definition). (hallek2018iwcllguidelinesfor pages 1-2) - Bone marrow (cytopenias from marrow failure are key treatment indications in iwCLL). (hallek2018iwcllguidelinesfor media 86780099) - Lymph nodes (lymphadenopathy is common). (shadman2023diagnosisandtreatment pages 1-2) - Spleen and liver (hepatosplenomegaly). (shadman2023diagnosisandtreatment pages 1-2)
Suggested UBERON mappings (examples): - Blood (UBERON:0000178) - Bone marrow (UBERON:0002371) - Lymph node (UBERON:0000029) - Spleen (UBERON:0002106) - Liver (UBERON:0002107)
iwCLL 2018 emphasizes Rai and Binet staging systems (clinical exam + labs) and integrated prognostic models. The CLL-IPI includes clinical stage, age, IGHV status, β2-microglobulin, and del(17p)/TP53. (hallek2018iwcllguidelinesfor pages 4-5)
Direct guideline text quote: “the CLL-IPI consists of … clinical stage, age, IGHV mutational status, serum β2-microglobulin, and the presence of del(17p) and/or TP53 mutations.” (hallek2018iwcllguidelinesfor pages 4-5)
From a 2023 JAMA review: - >200,000 people living with CLL in the US - ~4,410 deaths/year in the US - Male predominance ~1.7:1 - Approximate survival: ~90% 5-year, ~82% 10-year (shadman2023diagnosisandtreatment pages 1-2)
No single Mendelian inheritance pattern dominates; evidence supports polygenic susceptibility and rare germline risk variants in specific genes (e.g., ATM), with strong familial clustering but no common high-penetrance allele identified. (brown2024clinicalrisksfor pages 1-2)
Required blood criterion: iwCLL requires ≥5 × 10^9/L clonal B lymphocytes for ≥3 months, with flow cytometry confirmation. (hallek2018iwcllguidelinesfor pages 1-2)
Immunophenotyping panel: iwCLL notes a “panel of CD19, CD5, CD20, CD23, κ, and λ” is usually sufficient to establish diagnosis, with additional markers (CD43, CD79b, CD81, CD200, CD10, ROR1) for borderline cases. (hallek2018iwcllguidelinesfor pages 1-2)
iwCLL 2018 provides treatment-indication logic based on stage and “active disease,” including progressive marrow failure and symptomatic bulky disease; the guideline’s table/criteria were retrieved as an image (see cited figure region). (hallek2018iwcllguidelinesfor media 86780099)
Visual evidence: Cropped guideline table/criteria region from iwCLL 2018 is available. (hallek2018iwcllguidelinesfor media 86780099)
A 2023 JAMA review notes Richter transformation occurs “up to 10% … (0.5–1%/yr)” and is associated with poor median overall survival (OS) in heavily pretreated disease. (shadman2023diagnosisandtreatment pages 12-13)
A 2023 JAMA review states that first-line therapy for symptomatic disease consists of either: - a covalent BTK inhibitor (acalabrutinib, zanubrutinib, ibrutinib), or - a BCL2 inhibitor regimen based on venetoclax (commonly venetoclax + obinutuzumab) with no evidence that sequencing one class before the other improves outcomes. (shadman2023diagnosisandtreatment pages 1-2)
Direct abstract quote (JAMA 2023): “first-line treatment consists of a regimen containing either a covalent Bruton tyrosine kinase (BTK) inhibitor … or a … BCL2 inhibitor (venetoclax). There is no evidence that starting either class before the other improves outcomes.” (shadman2023diagnosisandtreatment pages 1-2)
The CLL14 5-year analysis (Nature Communications 2023) reports: - Median follow-up 65.4 months - PFS superior for Ven-Obi vs Clb-Obi: HR 0.35 (95% CI 0.26–0.46), p<0.0001 - 5-year PFS 62.6% (Ven-Obi) vs 27.0% (Clb-Obi) (alsawaf2023transcriptomicprofilesand pages 1-2)
Direct abstract quote: “At 5 years after randomization, the estimated PFS rate is 62.6% after Ven-Obi and 27.0% after Clb-Obi.” (alsawaf2023transcriptomicprofilesand pages 1-2)
In relapsed/refractory CLL/SLL, a 2024 Annals of Hematology report (ALPINE China subgroup) found: - ORR 80.9% zanubrutinib vs 72.1% ibrutinib - PFS improved with zanubrutinib: HR 0.34 (95% CI 0.15–0.77) - Lower discontinuation due to AEs: 6.4% vs 14.0% (zhou2024improvedefficacyand pages 1-2)
In BTKi-intolerant patients (BRUIN phase I/II), pirtobrutinib produced in CLL/SLL: - ORR 76.9% (78 patients) - Median PFS 28.4 months - Median follow-up 17.4 months with notable tolerability signals (e.g., no discontinuations for the same AE that caused prior BTKi discontinuation). (shah2024pirtobrutinibmonotherapyin pages 1-2)
CAR-T therapy with lisocabtagene maraleucel in multiply relapsed CLL was associated with 45% complete response in the JAMA summary. (shadman2023diagnosisandtreatment pages 1-2)
| Setting | Regimen / class | Key efficacy stats | Key safety notes | Duration strategy | Publication date | URL | Citations |
|---|---|---|---|---|---|---|---|
| Frontline, treatment-naive CLL requiring therapy | Acalabrutinib (covalent BTK inhibitor) | Survival rate approximately 88% at 4 years in first-line use; guideline-level summary identifies covalent BTKi as a standard first-line option (shadman2023diagnosisandtreatment pages 1-2) | Second-generation BTKi generally has fewer discontinuations and less atrial fibrillation than ibrutinib in comparative data summarized in the review; BTKi are used with attention to class toxicities including cardiac events, bleeding, arthralgia, rash, and infection risk (shadman2023diagnosisandtreatment pages 4-5, shadman2023diagnosisandtreatment pages 1-2) | Continuous / indefinite | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | (shadman2023diagnosisandtreatment pages 4-5, shadman2023diagnosisandtreatment pages 1-2) |
| Frontline, treatment-naive CLL requiring therapy | Zanubrutinib (covalent BTK inhibitor) | Survival rate approximately 94% at 2 years in first-line use; listed as a standard first-line covalent BTKi option (shadman2023diagnosisandtreatment pages 1-2) | Review summary indicates lower atrial fibrillation than ibrutinib, though neutropenia may be more frequent in some comparisons; newer BTKi generally favored over ibrutinib for safety (shadman2023diagnosisandtreatment pages 12-13, shadman2023diagnosisandtreatment pages 1-2) | Continuous / indefinite | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | (shadman2023diagnosisandtreatment pages 12-13, shadman2023diagnosisandtreatment pages 1-2) |
| Frontline, treatment-naive CLL requiring therapy | Ibrutinib (covalent BTK inhibitor) | Survival rate approximately 78% at 7 years in first-line use; remains an effective frontline BTKi option in review summaries (shadman2023diagnosisandtreatment pages 1-2) | Notable toxicity burden in review summary: arthralgia, atrial fibrillation, rash, bleeding/infection concerns; higher discontinuation than acalabrutinib in summarized comparisons (shadman2023diagnosisandtreatment pages 4-5, shadman2023diagnosisandtreatment pages 1-2) | Continuous / indefinite | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | (shadman2023diagnosisandtreatment pages 4-5, shadman2023diagnosisandtreatment pages 1-2) |
| Frontline, previously untreated CLL with coexisting conditions | Venetoclax + obinutuzumab (BCL2 inhibitor + anti-CD20) | CLL14: after median follow-up 65.4 months, PFS superior vs chlorambucil-obinutuzumab, HR 0.35 (95% CI 0.26-0.46; p<0.0001); 5-year PFS 62.6% vs 27.0%. JAMA review summarizes overall survival 82% at 5-year follow-up (alsawaf2023transcriptomicprofilesand pages 1-2, shadman2023diagnosisandtreatment pages 1-2) | End-of-treatment MRD positivity associated with shorter PFS; inflammatory response pathways enriched in MRD-positive patients in Ven-Obi arm. Requires venetoclax-specific monitoring in practice, including tumor lysis risk management (efficacy paper plus review context) (alsawaf2023transcriptomicprofilesand pages 1-2, shadman2023diagnosisandtreatment pages 1-2) | Fixed-duration, 1 year | 2023-04-13 | https://doi.org/10.1038/s41467-023-37648-w | (alsawaf2023transcriptomicprofilesand pages 1-2, shadman2023diagnosisandtreatment pages 1-2) |
| Relapsed/refractory CLL/SLL, China subgroup of ALPINE | Zanubrutinib vs ibrutinib (head-to-head covalent BTKi comparison) | With median follow-up 25.3 months, ORR 80.9% vs 72.1%; PFS HR 0.34 (95% CI 0.15-0.77) favoring zanubrutinib; OS HR 0.45 (95% CI 0.14-1.50) (zhou2024improvedefficacyand pages 1-2) | Lower rates with zanubrutinib vs ibrutinib of grade ≥3 TEAEs 64.4% vs 72.1%, AEs leading to discontinuation 6.4% vs 14.0%, and serious TEAEs 35.6% vs 51.2% (zhou2024improvedefficacyand pages 1-2) | Continuous until progression or unacceptable toxicity | 2024-06-18 | https://doi.org/10.1007/s00277-024-05823-8 | (zhou2024improvedefficacyand pages 1-2) |
| Relapsed/refractory B-cell malignancies; BTKi-intolerant CLL/SLL subset in BRUIN | Pirtobrutinib (non-covalent BTK inhibitor) | In 78 CLL/SLL patients intolerant to prior BTKi, ORR 76.9%; median PFS 28.4 months; median follow-up 17.4 months (shah2024pirtobrutinibmonotherapyin pages 1-2) | Most common prior BTKi-discontinuation reason was cardiac disorders, especially atrial fibrillation. On pirtobrutinib, frequent TEAE were fatigue 39.4% and neutropenia 37.0%; among patients who stopped prior BTKi for a cardiac issue, 75% had no recurrence of that cardiac AE; no patient discontinued pirtobrutinib for the same AE that caused prior BTKi discontinuation (shah2024pirtobrutinibmonotherapyin pages 1-2) | Continuous | Early view 2024-10-03; journal issue 2025-01 | https://doi.org/10.3324/haematol.2024.285754 | (shah2024pirtobrutinibmonotherapyin pages 1-2) |
| Multiply relapsed / heavily pretreated CLL | Lisocabtagene maraleucel CAR-T (cellular therapy) | JAMA review summary: CAR-T with lisocabtagene maraleucel associated with 45% complete response rate; separate review summary also notes TRANSCEND overall response 82% with durable MRD-negative remissions in blood and marrow in some patients (shadman2023diagnosisandtreatment pages 1-2, shadman2023diagnosisandtreatment pages 12-13) | Cytokine release syndrome and neurologic events are major toxicities highlighted in review summaries (shadman2023diagnosisandtreatment pages 12-13) | Finite cellular therapy | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | (shadman2023diagnosisandtreatment pages 12-13, shadman2023diagnosisandtreatment pages 1-2) |
Table: This table summarizes major contemporary CLL therapies across frontline and relapsed/refractory settings using only extracted evidence from the cited sources. It highlights efficacy, safety, treatment duration strategy, and publication metadata for rapid comparison.
No proven primary prevention strategy is established; risk-factor identification remains incomplete. (brown2024clinicalrisksfor pages 1-2)
Routine population screening is not supported by the evidence provided; many patients are managed with watchful waiting. (shadman2023diagnosisandtreatment pages 1-2, brown2024clinicalrisksfor pages 1-2)
CLL is associated with immunocompromise and infection complications. The 2023 JAMA review recommends vaccination against influenza, pneumococcus, COVID-19, and varicella zoster for CLL patients, and notes IVIG can benefit those with hypogammaglobulinemia and recurrent infections. (shadman2023diagnosisandtreatment pages 4-5, shadman2023diagnosisandtreatment pages 1-2)
Direct evidence for naturally occurring CLL-like disease in non-human species was not retrieved in the current corpus.
Multiple 2024 primary studies explicitly used Eμ-TCL1 mice as an in vivo model of CLL pathophysiology: - Microbiome diversity influences CLL development kinetics in Eμ-TCL1 mice. (faitova2024thediversityof pages 1-2) - Conditioned media from leukemic cells from Eμ-TCL1 mice induce PD-1 upregulation and CTL dysfunction; IL-9 mediates immune suppression. (boncompagni2024leukemiccellsecretedinterleukin9 pages 1-3) - NFKBIE-mutant functional studies use Eμ-TCL1-derived murine leukemia lines and in vivo models to link microenvironmental selection, immune escape, and BTKi response. (bonato2024nfkbiemutationsare pages 1-2)
Evidence types include in vivo murine models and human patient sample analyses (microbiome cohort of 59 CLL patients; immune suppression studies include human CLL patient-derived leukemic cells and mouse). (faitova2024thediversityof pages 1-2, boncompagni2024leukemiccellsecretedinterleukin9 pages 1-3)
| Domain | Item | Key data / finding | Publication date | URL | Evidence type | PaperQA citation IDs |
|---|---|---|---|---|---|---|
| Definition / diagnosis | Core CLL diagnostic threshold | CLL requires >=5 × 10^9/L clonal B lymphocytes in peripheral blood, sustained for at least 3 months; clonality confirmed by light-chain restriction on flow cytometry | 2018-06-21 | https://doi.org/10.1182/blood-2017-09-806398 | Guideline / consensus criteria | (hallek2018iwcllguidelinesfor pages 1-2, hallek2018iwcllguidelinesfor media 015ffd7a) |
| Guideline source | iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL | International consensus guideline updating diagnosis, MRD, prognostic genetics, response criteria, and supportive management | 2018-06-21 | https://doi.org/10.1182/blood-2017-09-806398 | Guideline / consensus statement | (hallek2018iwcllguidelinesfor pages 1-2, hallek2018iwcllguidelinesfor pages 4-5) |
| Guideline source | JAMA review: Diagnosis and Treatment of Chronic Lymphocytic Leukemia | High-level clinical review summarizing modern diagnosis, prognosis, treatment indications, and targeted therapies | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | Peer-reviewed clinical review | (shadman2023diagnosisandtreatment pages 1-2) |
| Epidemiology | People living with CLL in the US | >200,000 people in the US living with a CLL diagnosis | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | Review citing US epidemiology | (shadman2023diagnosisandtreatment pages 1-2) |
| Epidemiology | Annual US deaths | Approximately 4,410 deaths/year in the US | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | Review citing US epidemiology | (shadman2023diagnosisandtreatment pages 1-2) |
| Epidemiology | Median age at diagnosis | 70 years | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | Review / clinical summary | (shadman2023diagnosisandtreatment pages 1-2) |
| Epidemiology / presentation | Asymptomatic at diagnosis | Approximately 70%–80% asymptomatic at diagnosis | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | Review / clinical summary | (shadman2023diagnosisandtreatment pages 1-2) |
| Presenting features | Incidental lymphocytosis | Asymptomatic incidental lymphocytosis in about 70% at presentation | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | Review (Box 1) | (shadman2023diagnosisandtreatment pages 1-2) |
| Presenting features | Enlarged lymph nodes | Approximately 50% | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | Review (Box 1) | (shadman2023diagnosisandtreatment pages 1-2) |
| Presenting features | Enlarged spleen or liver | Approximately 20%–50% | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | Review (Box 1) | (shadman2023diagnosisandtreatment pages 1-2) |
| Presenting features | Constitutional/B symptoms | Fever / drenching night sweats / >=10% weight loss within 6 months in about 5%–10% | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | Review (Box 1) | (shadman2023diagnosisandtreatment pages 1-2) |
| Presenting features | Autoimmune hemolytic anemia | Up to 10% | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | Review (Box 1) | (shadman2023diagnosisandtreatment pages 1-2) |
| Presenting features | Immune thrombocytopenia | Up to 2% | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | Review (Box 1) | (shadman2023diagnosisandtreatment pages 1-2) |
| Presenting features | Hypogammaglobulinemia with frequent infections | Up to 10% | 2023-03-21 | https://doi.org/10.1001/jama.2023.1946 | Review (Box 1) | (shadman2023diagnosisandtreatment pages 1-2) |
| Prognostic genetics / cytogenetics | del(13q14) | Most common cytogenetic lesion, about 55% | 2019-11 | https://doi.org/10.1002/ajh.25595 | Review / risk-stratification summary | (hallek2019chroniclymphocyticleukemia pages 1-2) |
| Prognostic genetics / cytogenetics | Trisomy 12 | Approximately 10%–20% | 2019-11 | https://doi.org/10.1002/ajh.25595 | Review / risk-stratification summary | (hallek2019chroniclymphocyticleukemia pages 1-2) |
| Prognostic genetics / cytogenetics | del(17p) in untreated / chemo-naive disease | Approximately 5%–8% in chemo-naive patients; usually implicates TP53 loss/disruption and predicts poor response to chemoimmunotherapy | 2019-11 | https://doi.org/10.1002/ajh.25595 | Review / prognostic genetics summary | (hallek2019chroniclymphocyticleukemia pages 1-2) |
Table: This table condenses core CLL definition, guideline sources, epidemiology, presenting features, and major prognostic cytogenetic frequencies into a single quick-reference artifact. It is designed to support knowledge-base population with directly citable evidence and URLs.
A cropped image region from iwCLL 2018 capturing the diagnostic threshold and treatment-indication framework (“active disease” criteria) was retrieved. (hallek2018iwcllguidelinesfor media 015ffd7a, hallek2018iwcllguidelinesfor media 86780099)
References
(hallek2019chroniclymphocyticleukemia pages 1-2): Michael Hallek. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. American Journal of Hematology, 94:1266-1287, Nov 2019. URL: https://doi.org/10.1002/ajh.25595, doi:10.1002/ajh.25595. This article has 750 citations and is from a domain leading peer-reviewed journal.
(hallek2018iwcllguidelinesfor pages 1-2): Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R. Rai, John C. Byrd, Barbara Eichhorst, Susan O’Brien, Tadeusz Robak, John F. Seymour, and Thomas J. Kipps. Iwcll guidelines for diagnosis, indications for treatment, response assessment, and supportive management of cll. Blood, 131 25:2745-2760, Jun 2018. URL: https://doi.org/10.1182/blood-2017-09-806398, doi:10.1182/blood-2017-09-806398. This article has 2326 citations and is from a highest quality peer-reviewed journal.
(shadman2023diagnosisandtreatment pages 1-2): Mazyar Shadman. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA, 329 11:918-932, Mar 2023. URL: https://doi.org/10.1001/jama.2023.1946, doi:10.1001/jama.2023.1946. This article has 270 citations.
(zhou2024improvedefficacyand pages 1-2): Keshu Zhou, Tingyu Wang, Ling Pan, Wei Xu, Jie Jin, Wei Zhang, Yu Hu, Jianda Hu, Ru Feng, Ping Li, Zhougang Liu, Peng Liu, Hongmei Jing, Sujun Gao, Huilai Zhang, Kang Yu, Zhao Wang, Xiongpeng Zhu, Zimin Sun, Fei Li, Dongmei Yan, Jianyu Weng, Lina Fu, Liping Wang, Tommi Salmi, Kenneth Wu, and Lugui Qiu. Improved efficacy and safety of zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia (r/r cll) in china: a subgroup of alpine. Annals of Hematology, 103:4183-4191, Jun 2024. URL: https://doi.org/10.1007/s00277-024-05823-8, doi:10.1007/s00277-024-05823-8. This article has 8 citations and is from a peer-reviewed journal.
(brown2024clinicalrisksfor pages 1-2): Jennifer R. Brown. Clinical risks for chronic lymphocytic leukemia. Journal of the National Comprehensive Cancer Network : JNCCN, Apr 2024. URL: https://doi.org/10.6004/jnccn.2024.7020, doi:10.6004/jnccn.2024.7020. This article has 7 citations.
(mansouri2023differentprognosticimpact pages 1-2): Larry Mansouri, Birna Thorvaldsdottir, Lesley-Ann Sutton, Georgios Karakatsoulis, Manja Meggendorfer, Helen Parker, Ferran Nadeu, Christian Brieghel, Stamatia Laidou, Riccardo Moia, Davide Rossi, Mark Catherwood, Jana Kotaskova, Julio Delgado, Ana E. Rodríguez-Vicente, Rocío Benito, Gian Matteo Rigolin, Silvia Bonfiglio, Lydia Scarfo, Mattias Mattsson, Zadie Davis, Ajay Gogia, Lata Rani, Panagiotis Baliakas, Hassan Foroughi-Asl, Cecilia Jylhä, Aron Skaftason, Inmaculada Rapado, Fatima Miras, Joaquín Martinez-Lopez, Javier de la Serna, Jesús María Hernández Rivas, Patrick Thornton, María José Larráyoz, María José Calasanz, Viktória Fésüs, Zoltán Mátrai, Csaba Bödör, Karin E. Smedby, Blanca Espinet, Anna Puiggros, Ritu Gupta, Lars Bullinger, Francesc Bosch, Bárbara Tazón-Vega, Fanny Baran-Marszak, David Oscier, Florence Nguyen-Khac, Thorsten Zenz, Maria Jose Terol, Antonio Cuneo, María Hernández-Sánchez, Sarka Pospisilova, Ken Mills, Gianluca Gaidano, Carsten U. Niemann, Elias Campo, Jonathan C. Strefford, Paolo Ghia, Kostas Stamatopoulos, and Richard Rosenquist. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on ighv gene somatic hypermutation status: a study by eric in harmony. Leukemia, 37:339-347, Dec 2023. URL: https://doi.org/10.1038/s41375-022-01802-y, doi:10.1038/s41375-022-01802-y. This article has 73 citations and is from a highest quality peer-reviewed journal.
(bonato2024nfkbiemutationsare pages 1-2): Alice Bonato, Supriya Chakraborty, Riccardo Bomben, Giulia Canarutto, Giulia Felician, Claudio Martines, Antonella Zucchetto, Federico Pozzo, Marija Vujovikj, Jerry Polesel, Annalisa Chiarenza, Maria Ilaria Del Principe, Giovanni Del Poeta, Giovanni D’Arena, Roberto Marasca, Agostino Tafuri, Luca Laurenti, Silvano Piazza, Aleksandar J. Dimovski, Valter Gattei, and Dimitar G. Efremov. Nfkbie mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia. Leukemia, 38:1511-1521, Mar 2024. URL: https://doi.org/10.1038/s41375-024-02224-8, doi:10.1038/s41375-024-02224-8. This article has 20 citations and is from a highest quality peer-reviewed journal.
(boncompagni2024leukemiccellsecretedinterleukin9 pages 1-3): Gioia Boncompagni, Vanessa Tatangelo, Ludovica Lopresti, Cristina Ulivieri, Nagaja Capitani, Carmela Tangredi, Francesca Finetti, Giuseppe Marotta, Federica Frezzato, Andrea Visentin, Sara Ciofini, Alessandro Gozzetti, Monica Bocchia, Diego Calzada-Fraile, Noa B. Martin Cofreces, Livio Trentin, Laura Patrussi, and Cosima T. Baldari. Leukemic cell-secreted interleukin-9 suppresses cytotoxic t cell-mediated killing in chronic lymphocytic leukemia. Cell Death & Disease, Feb 2024. URL: https://doi.org/10.1038/s41419-024-06528-6, doi:10.1038/s41419-024-06528-6. This article has 10 citations and is from a peer-reviewed journal.
(faitova2024thediversityof pages 1-2): Tereza Faitova, Mariana Coelho, Caspar Da Cunha-Bang, Selcen Ozturk, Ece Kartal, Peer Bork, Martina Seiffert, and Carsten U. Niemann. The diversity of the microbiome impacts chronic lymphocytic leukemia development in mice and humans. Haematologica, 109:3237-3250, May 2024. URL: https://doi.org/10.3324/haematol.2023.284693, doi:10.3324/haematol.2023.284693. This article has 12 citations.
(hallek2018iwcllguidelinesfor media 86780099): Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R. Rai, John C. Byrd, Barbara Eichhorst, Susan O’Brien, Tadeusz Robak, John F. Seymour, and Thomas J. Kipps. Iwcll guidelines for diagnosis, indications for treatment, response assessment, and supportive management of cll. Blood, 131 25:2745-2760, Jun 2018. URL: https://doi.org/10.1182/blood-2017-09-806398, doi:10.1182/blood-2017-09-806398. This article has 2326 citations and is from a highest quality peer-reviewed journal.
(hallek2018iwcllguidelinesfor pages 4-5): Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R. Rai, John C. Byrd, Barbara Eichhorst, Susan O’Brien, Tadeusz Robak, John F. Seymour, and Thomas J. Kipps. Iwcll guidelines for diagnosis, indications for treatment, response assessment, and supportive management of cll. Blood, 131 25:2745-2760, Jun 2018. URL: https://doi.org/10.1182/blood-2017-09-806398, doi:10.1182/blood-2017-09-806398. This article has 2326 citations and is from a highest quality peer-reviewed journal.
(shadman2023diagnosisandtreatment pages 12-13): Mazyar Shadman. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA, 329 11:918-932, Mar 2023. URL: https://doi.org/10.1001/jama.2023.1946, doi:10.1001/jama.2023.1946. This article has 270 citations.
(alsawaf2023transcriptomicprofilesand pages 1-2): Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi, Sandhya Balasubramanian, Alex Kotak, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Brenda Chyla, Joseph N. Paulson, Christian P. Pallasch, Lukas P. Frenzel, Martin Peifer, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, and Kirsten Fischer. Transcriptomic profiles and 5-year results from the randomized cll14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nature Communications, Apr 2023. URL: https://doi.org/10.1038/s41467-023-37648-w, doi:10.1038/s41467-023-37648-w. This article has 124 citations and is from a highest quality peer-reviewed journal.
(shah2024pirtobrutinibmonotherapyin pages 1-2): Nirav N. Shah, Michael Wang, Lindsey E. Roeker, Krish Patel, Jennifer A. Woyach, William G. Wierda, Chaitra S. Ujjani, Toby A. Eyre, Pier Luigi Z Inzani, Alvaro J. Alencar, Paolo Ghia, Nicole Lamanna, Marc S. Hoffmann, Manish R. Patel, Ian Flinn, James N. Gerson, Shuo Ma, Catherine C. Coombs, Chan Y. Cheah, Ewa Lech-Maranda, Bita Fakhri, Won Seog Kim, Minal A. Barve, Jonathon B. Cohen, Wojciech Jurczak, Talha Munir, Meghan C. Thompson, Donald E. Tsai, Katherine Bao, Nicholas A. Cangemi, Jennifer F. Kherani, Richard A. Walgren, Hongmei Han, Amy S. Ruppert, and Jennifer R. Brown. Pirtobrutinib monotherapy in bruton tyrosine kinase inhibitor-intolerant patients with b-cell malignancies: results of the phase i/ii bruin trial. Haematologica, 110:92-102, Oct 2024. URL: https://doi.org/10.3324/haematol.2024.285754, doi:10.3324/haematol.2024.285754. This article has 21 citations.
(shadman2023diagnosisandtreatment pages 4-5): Mazyar Shadman. Diagnosis and treatment of chronic lymphocytic leukemia: a review. JAMA, 329 11:918-932, Mar 2023. URL: https://doi.org/10.1001/jama.2023.1946, doi:10.1001/jama.2023.1946. This article has 270 citations.
(hallek2018iwcllguidelinesfor media 015ffd7a): Michael Hallek, Bruce D. Cheson, Daniel Catovsky, Federico Caligaris-Cappio, Guillermo Dighiero, Hartmut Döhner, Peter Hillmen, Michael Keating, Emili Montserrat, Nicholas Chiorazzi, Stephan Stilgenbauer, Kanti R. Rai, John C. Byrd, Barbara Eichhorst, Susan O’Brien, Tadeusz Robak, John F. Seymour, and Thomas J. Kipps. Iwcll guidelines for diagnosis, indications for treatment, response assessment, and supportive management of cll. Blood, 131 25:2745-2760, Jun 2018. URL: https://doi.org/10.1182/blood-2017-09-806398, doi:10.1182/blood-2017-09-806398. This article has 2326 citations and is from a highest quality peer-reviewed journal.